source
- Recon: Sino, Boehringer ink cancer drug deal worth $7B; CVS to split pharmacy business from insuranceWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 5d ago↗ source
- Novo Nordisk lifts 2026 profit outlook after Wegovy obesity pill beats forecastsNovo Nordisk announced on Wednesday that it is raising its full-year profit and sales guidance after the third-quarter results for its Wegovy obesity pill came in above analysts' expectations. The…